Tectonic Therapeutic TECX
NASDAQ TECX
$30.03 +0.11 (+0.37%)
As of: Sep 4, 2026 · 12:30 PM EDT

Tectonic Therapeutic (TECX) Income from Non-Controlling Interests (2023 - 2026)

Tectonic Therapeutic (TECX) posted quarterly Income from Non-Controlling Interests of $25.2 million for Q1 2026, up 58.39% year-over-year from $15.9 million in Q1 2025, and up 30.95% quarter-over-quarter from $19.2 million in Q4 2025.

Analysis

Tectonic Therapeutic (TECX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends

Tectonic Therapeutic (TECX) has reported Income from Non-Controlling Interests for 4 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Income from Non-Controlling Interests rose 58.39% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $83.5 million (up 42.52% YoY), while the FY2025 annual figure was $74.3 million, up 28.09% from the prior year.
  • Income from Non-Controlling Interests rose to $25.2 million in Q1 2026 per TECX's latest filing, from $19.2 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $25.2 million in Q1 2026 and bottomed at $7.9 million in Q4 2023.
  • Historically, Income from Non-Controlling Interests has averaged $15.5 million across 4 years, with a median of $15.6 million in 2024.
  • Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests soared 76.38% — and 2025, when it advanced 4.2%.
  • Tectonic Therapeutic's Income from Non-Controlling Interests stood at $7.9 million in 2023, then soared by 56.07% to $12.3 million in 2024, then jumped by 56.51% to $19.2 million in 2025, then surged by 30.95% to $25.2 million in 2026.
  • Business Quant data shows TECX's Income from Non-Controlling Interests at $25.2 million in Q1 2026, $19.2 million in Q4 2025, and $19.1 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn -
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn -
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn -
8 Royalty Pharma 28.52 Bn 27.68 Bn - 63.60 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -
10 Tectonic Therapeutic 569.49 Mn 569.49 Mn - 22.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 22.29 Mn
Mar 31, 2026 25.20 Mn
Dec 31, 2025 19.25 Mn
Sep 30, 2025 19.06 Mn
Jun 30, 2025 20.04 Mn
Mar 31, 2025 15.91 Mn
Dec 31, 2024 12.30 Mn
Sep 30, 2024 17.73 Mn
Jun 30, 2024 12.68 Mn
Mar 31, 2024 15.27 Mn
Dec 31, 2023 7.88 Mn
Sep 30, 2023 10.05 Mn
Jun 30, 2023 10.46 Mn